2月12日 - ** 远程医疗公司Hims & Hers Health HIMS.N的股价在下午的交易中下跌4%至16.01美元，有望连续第十天下跌。
* (link) * 上周，HIMS表示将在 (link)，这是诺和诺德公司（Novo Nordisk）用于减肥的Wegovy药片的49美元复方版本，但在美国卫生监管机构的审查后， (link)。
** 丹麦制药商诺和诺德起诉 (link) HIMS 侵犯 Wegovy 的活性成分 semaglutide 的专利权后，该公司股价进一步下跌。
** 诺和诺德已经起诉了几家复方制剂生产商，指控其销售不安全、虚假宣传的Wegovy "山寨版"，侵犯了诺和诺德的商标权，但HIMS公司的诉讼是诺和诺德在美国针对复方制剂生产商的第一起专利侵权案。
** 截至收盘，HIMS 累计下跌 50
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.